JAMA Oncology Author Interviews

Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Dec 23, 2021

22:38

forum

Ask episode

view_agenda

Chapters

auto_awesome

Transcript

info_circle

Episode notes

Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.

Home Top podcasts Popular guests Top books